Dyadic International (DYAI) EBIT Growth (3y) (2021 - 2026)
Powered by 
Analysis
Dyadic International (DYAI) EBIT Growth (3y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 9.40% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -102.00% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 6.70% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 8.36% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 89.72% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 24.14% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 44.34% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -96.48% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Dyadic International | 17.78 Mn | 9.82 Mn | - | 2.46% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 2.46% |
| Dec 31, 2025 | 11.81% |
| Sep 30, 2025 | -1.10% |
| Jun 30, 2025 | 19.53% |
| Mar 31, 2025 | 9.98% |
| Dec 31, 2024 | 28.67% |
| Sep 30, 2024 | 60.64% |
| Jun 30, 2024 | 19.16% |
| Mar 31, 2024 | 91.38% |
| Dec 31, 2023 | 1.49% |
| Sep 30, 2023 | 12.60% |
| Jun 30, 2023 | 6.45% |
| Mar 31, 2023 | 4.88% |
| Dec 31, 2022 | -4.97% |
| Sep 30, 2022 | 1.39% |
| Jun 30, 2022 | -3.86% |
| Mar 31, 2022 | -3.98% |
| Dec 31, 2021 | -33.66% |
| Sep 30, 2021 | -23.12% |
| Jun 30, 2021 | -28.65% |